Safety Alerts & Recalls

What does this mean?

Although there is conflicting information about whether abacavir treatment increases the risk of heart attack, the FDA’s recent review found no difference in heart attack events between patients who received abacavir and those who did not.

If you take abacavir (Ziagen) or a product containing abacavir (Trizivir or Epzicom), you should continue to take your medicine as directed by your healthcare professional. Please discuss any questions or concerns about abacavir with your healthcare professional.

FDA Review of Abacavir Finds No Increased Risk of Heart Attack

The Food and Drug Administration (FDA) updated the public about an ongoing safety review of abacavir and a possible increased risk of heart attack (also known as myocardial infarction or MI) seen in some research studies, but not in others. The FDA reviewed 26 randomized clinical trials, and did not find an increased risk of heart attack associated with the use of abacavir. The FDA will continue to communicate any new safety information to the public as it becomes available.

Abacavir is an antiviral medication used in combination with other antiretroviral drugs for the treatment of HIV-1 infection. Abacavir is sold under the brand name Ziagen and is also sold in combination with other antiretroviral drugs under the names Trizivir and Epzicom.

For more information, please visit: more information here

Source: FDA
Publication Date: 2011-03-01
Last Updated: 2011-03-01

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.